Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease

Pharmacogenomics. 2023 May;24(7):359-369. doi: 10.2217/pgs-2023-0045. Epub 2023 May 30.

Abstract

Background: Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge in patient care. Materials & methods: The authors conducted a cross-sectional study to determine the effect of CYP2D6 and UGT2B7 polymorphisms on pain management in 106 Zimbabwean SCD patients. Participant information was collected on a questionnaire. Genotyping was conducted using the GenoPharm® pharmacogenomics open array panel containing CYP2D6 and UGT genetic variants implicated in opioid response. Results: The reduced function alleles CYP2D6*17 and *29 had high frequencies of 15.9% and 12.9%, respectively. UGT2B7 rs73823859 showed a statistically significant correlation with pain levels (p = 0.0454). Conclusion: This study demonstrated the role of UGT2B7 polymorphism in SCD patient pain management.

Keywords: CYP2D6; UGT2B7; codeine; genetic variation; morphine; opioids; pharmacogenomics; tramadol.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Anemia, Sickle Cell* / complications
  • Anemia, Sickle Cell* / drug therapy
  • Anemia, Sickle Cell* / genetics
  • Cross-Sectional Studies
  • Cytochrome P-450 CYP2D6 / genetics
  • Humans
  • Pain / drug therapy
  • Pain / genetics
  • Pain Management
  • Pharmacogenetics*
  • Zimbabwe

Substances

  • Cytochrome P-450 CYP2D6
  • Analgesics, Opioid